An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study (Q85232838)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 September 2014

Language	Label	Description	Also known as
English	An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study	scientific article published on 02 September 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

L Klotz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

D Drachenberg

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

R Singal

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

A Aprikian

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

Y Fradet

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

M Kebabdjian

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

M Zarenda

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

J Chin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

publication date

2 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

320-324

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25179591 AND SRC:MED&resulttype=core&format=json

15 February 2020

Maximal androgen blockade for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Combined androgen blockade in advanced prostate cancer: looking back to move forward

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Combined androgen blockade: the case for bicalutamide

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

The role of diethylstilbestrol in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Hormone/Antihormone Withdrawal and Dexamethasone for Hormone‐Refractory Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Transcriptional repression by nuclear hormone receptors

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Molecular determinants of resistance to antiandrogen therapy

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Castration-recurrent prostate cancer is not androgen-independent

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Bicalutamide dosages used in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health‐related quality of life benefits for osteoporotic men with prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

31 March 2020

A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical adrenalectomy for advanced prostatic cancer: clinical and hormonal effects

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of prostate-specific antigen as a predictor of outcome in prostate cancer

1 reference

https://api.crossref.org/works/10.1038/PCAN.2014.24

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85232838&oldid=2221725273"